Cancer Drug Supplier’s IPO Mints China’s Latest Billionaire

0

Today’s listing at the Shanghai Stock Exchange by Sichuan Biokin Pharmaceutical, a supplier of cancer drugs, has minted China’s latest billionaire.

Chairman Zhu Yi directly owns 298.1 million shares, worth 10 billion yuan, or $1.5 billion in early afternoon trading. Shares rose 36% from their IPO price to 33.69 yuan.

Zhu, 59, holds an undergraduate degree in radio technology, as well as a master’s degree in biology from Fudan University and a doctorate in management from Sichuan University. He taught immunology and microbiology at West China Medical University in 1987-1990.

Zhu founded Biokin in 1996. It operates in the U.S. through a Redmond, Washington-based subsidiary, Systimmune. China securities regulators approved Biokin’s IPO in December.

The country and the U.S. rank No. 1 and No. 2 in the number of cancer patients and overall cancer burden. China is home to the world’s second-largest number of billionaires after the United States.

— with Julie Lu

See related posts:

U.S., China Advance Discussions To Accelerate Cancer Drug Trials

China’s Richest See Record Plunge In Wealth

New Questions Arise For U.S. Businesses In China After “Jarring” End To Zero-Covid Policy

@rflannerychina

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health & Fitness News Click Here 

Read original article here

Denial of responsibility! Rapidtelecast.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave a comment